(3aS,4S,6aR)-2-oxo-4-(5-oxopentyl)-3,3a,6,6a-tetrahydro-1H-thieno[3,4-d]imidazole-4-carboxylic acid - patents, research & applications

758Patents

67Research papers

0Patents - last 3 years

0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Takeda Pharmaceutical Co Ltd	46
2	Roche Holding AG	27
3	Pfizer Inc	24
4	University of California	24
5	GSK PLC	19

6	Yale University	19
7	Agilent Technologies Inc	17
8	University of Pennsylvania	15
9	The Pennsylvania State University	13
10	Eli Lilly and Co	12

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`C07K`	Peptides	372
2	`G01N`	Investigating / analysing materials	286
3	`A61K`	Medicinal preparations	262
4	`C12N`	Microorganisms, enzymes	250
5	`A61P`	Therapeutic activity (drug indications)	224

6	`C12Q`	Measuring/testing involving enzymes	190
7	`Y10S`	Cross-reference (legacy)	76
8	`C40B`		61
9	`C07D`	Heterocyclic compounds	47
10	`Y10T`	Cross-reference (technical subjects)	45

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Representative patents

The filings that best characterise the patent activity around this compound, most-referenced first.

Title	Year	Assignee	Cited by
Directed evolution of novel binding proteins	1993	Takeda Pharmaceutical Co Ltd	6,565
Viruses expressing chimeric binding proteins	1995	Takeda Pharmaceutical Co Ltd	2,751
Method for enhancing transmembrane transport of exogenous molecules	1995	Purdue University System	1,113
Modified avidin-biotin technique	1994	University of Pennsylvania	1,082
SYSTEM AND METHODS FOR MASSIVELY PARALLEL ANALYSIS OF NYCLEIC ACIDS IN SINGLE CELLS	2012	Grifols SA	464

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Janos Zempleni	University of Nebraska–Lincoln	3
2	Nicola Waddell	QIMR Berghofer Medical Research Institute	2
3	Avadhesha Surolia	National Institute of Immunology	2
4	Logan C. Walker	QIMR Berghofer Medical Research Institute	2
5	Sean M. Grimmond	The University of Queensland	2

6	Sudha Purushothaman	Indian Institute of Science Bangalore	2
7	Amanda B. Spurdle	QIMR Berghofer Medical Research Institute	2
8	kConFab Investigators	Peter MacCallum Cancer Centre	2
9	Julio J. Caramelo	Universidad de Buenos Aires	1
10	Andrea H. Brand	Wellcome Trust	1

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
Global Sequencing of Proteolytic Cleavage Sites in Apoptosis by Specific Labeling of Protein N Termini	2008	468	Cell death mechanisms and regulation
Biotinylation reagents for the study of cell surface proteins	2008	207	Cellular transport and secretion
Botulinum Neurotoxin Detection and Differentiation by Mass Spectrometry	2005	186	Neurological disorders and treatments
Biotin−Streptavidin-Induced Aggregation of Gold Nanorods: Tuning Rod−Rod Orientation	2005	161	Gold and Silver Nanoparticles Synthesis and Applications
Design of Luminescent Biotinylation Reagents Derived from Cyclometalated Iridium(III) and Rhodium(III) Bis(pyridylbenzaldehyde) Complexes	2010	139	Advanced biosensing and bioanalysis techniques

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of this compound?

The compound has a molecular formula of C11H16N2O4S and a molecular weight of 272.319 g/mol.

Which organizations hold the most patents related to this compound?

The leading patent holders are Takeda Pharmaceutical Co Ltd with 46 patents, Roche Holding AG with 27 patents, and Pfizer Inc with 24 patents. Academic institutions are also significant contributors, with University of California and Yale University each holding 24 patents.

What are the primary technology areas associated with patents covering this compound?

The patents are primarily classified under C07K (organic chemistry of peptides and proteins, 372 patents), G01N (measuring and testing, 286 patents), A61K (medicinal preparations, 262 patents), and C12N (biochemistry and microbiology, 250 patents). These classifications indicate applications in biotechnology, pharmaceutical development, and analytical methods.

What is the current research activity level for this compound?

There have been no patents filed and no papers published on this compound in the last 3 years. Historically, the compound has been covered by 758 total patents and 67 papers, indicating that active research and development related to this compound has concluded.

Who are the most prolific authors publishing on topics related to this compound?

Janos Zempleni from University of Nebraska–Lincoln is the leading author with 3 papers. Multiple authors have contributed 2 papers each, including Nicola Waddell and Logan C. Walker from QIMR Berghofer Medical Research Institute, Sean M. Grimmond from The University of Queensland, and Amanda B. Spurdle also from QIMR Berghofer Medical Research Institute.